Constellation Brands' beer engine just stalled to +1% as Modelo and Corona shrink

---

For ten years, Constellation Brands was the cleanest growth story in a dying category. American beer consumption was in secular decline, yet Constellation's Mexican import portfolio — Modelo Especial, Corona, Pacifico — grew shipments, took share, raised prices, and expanded margins, year after year, like a fintech disrupter that happened to brew lager. The narrative wrote itself: Hispanic demographic tailwinds, premiumization, the slow coronation of Modelo Especial as the number-one beer by dollars in the United States. Investors paid a staples-plus multiple for what they were told was a structural-growth machine bolted onto a defensive category. The wine and spirits business was an afterthought; the Canopy cannabis adventure was a footnote they had already learned to ignore.

On April 8, 2026, Constellation reported its fiscal 2026 results for the year ended February 28, and the structural-growth machine reported numbers that a structural-growth machine does not report. Consolidated net sales fell roughly 10% to $9.14 billion. The wine and spirits segment — once a third of the company — cratered 58% as management dismantled and sold it. And the beer business, the entire reason to own this stock, grew net sales just 1% in the fourth quarter and declined 3% for the full year to $8.32 billion. Shipment volumes fell 3.8%. Depletions — the rate at which distributors sell to retailers, the truest read on real demand — fell 2.1%. This piece is about what happens to a one-engine company when the engine stops climbing, and why the comforting story investors are still telling themselves about Constellation is a story the fiscal 2026 income statement no longer supports.

The growth engine is now a flat engine

Begin with the single number that matters most, because everything else in the Constellation thesis is downstream of it: beer growth. For a decade, the beer segment compounded shipments at a mid-single-digit-or-better clip, and that compounding was the justification for the multiple, the leverage, and the patience investors extended to every other part of the business. Take away beer growth and Constellation is a slow-melting alcohol conglomerate with a debt load and a cannabis scar. Beer growth was the thesis.

In fiscal 2026, beer net sales fell 3% for the full year, with shipment volumes down 3.8%, partially cushioned by favorable pricing and mix. In the fourth quarter specifically, beer net sales managed a 1% increase to roughly $1.73 billion — and management's framing of that 1% as resilience is itself the tell. A company whose investment case is built on structural volume growth does not celebrate a 1% top line and a full-year volume decline as a win unless the alternative framing — that the engine has stalled — is one it badly needs to avoid. The forward guidance confirms it: management guided fiscal-year beer revenue to a band of negative 1% to positive 1%, explicitly citing "high volatility and low visibility for the consumer environment." A growth company does not guide its growth engine to a flat line straddling zero. That is the guidance of a business that has lost the one attribute that defined it.

Modelo and Corona — the brands the whole story rests on — are in decline

Here is where the forensic reader has to go past the segment header and into the brand-level depletions, because that is where the bull case quietly dies. The Constellation story has never really been about "beer." It has been about two brands: Modelo Especial, the dollar-share champion, and Corona, the iconic franchise. If those two are growing, the multiple is defensible. If they are shrinking, then everything bullish about Constellation is being carried by labels most investors could not name.

The fiscal 2026 depletion data says the two pillars are eroding. Full-year depletions for Modelo Especial fell approximately 3%. Corona Extra fell approximately 7%. The Modelo Chelada line fell roughly 1%. The only reason segment depletions declined a relatively contained 2.1% rather than something uglier is that secondary brands picked up the slack: Pacifico depletions grew over 15%, Victoria over 16%. Read that decomposition carefully. The number-one beer in America by dollars is in volume decline. The iconic Corona franchise is in high-single-digit decline. And the segment is being held together by Pacifico and Victoria — fine brands, but a fraction of the size, and brands that cannot individually move a $7-billion beer business. This is the demonstration-versus-deployment problem inverted: the brands that prove the thesis are shrinking, and the brands papering over the shrinkage are too small to carry it. When your two flagships are declining and your growth comes from labels with one-fifth the scale, you do not have a premiumization story. You have a portfolio rotating toward its weaker hand.

The wine-and-spirits "divestiture" tells you what management thinks of organic growth

Now look at what Constellation did with the rest of the company, because corporate actions reveal conviction more honestly than earnings calls do. The wine and spirits segment — which once represented roughly a third of Constellation's revenue and was, for years, marketed as a premiumization growth vector in its own right — saw net sales fall 58% in fiscal 2026, driven by a staggering 72.9% decline in shipment volumes. That collapse is not a demand event. It is a deliberate dismantling: management sold off large swaths of the wine and spirits portfolio, restructured distributor obligations, and took strategic pricing actions to shed brands it no longer wanted.

The bull will call this discipline — pruning low-growth assets to concentrate on beer. Fair enough as far as it goes. But step back and ask what the divestiture actually signals. Constellation paid up over the years to build a premium wine and spirits franchise on the explicit promise that it, too, could grow. It could not. So management is selling it, in some cases for a fraction of what was paid, and the company that emerges is more concentrated on the single beer engine, not less. The diversification that staples investors prize — the idea that if one category stumbles another picks up the slack — has been deliberately surrendered. Constellation has chosen to become a pure bet on Mexican import beer at precisely the moment that import beer franchise is posting its first negative depletion year in memory. That is not a hedge being trimmed. That is the company removing its own airbags right before the road gets rough.

The margin story is cracking too

For years the beer segment's other selling point was margin — not just growth, but expanding growth, the rare combination that justifies a premium multiple. That story is also under pressure. In the fourth quarter, consolidated operating margin fell 340 basis points to 33.2%, hit by unfavorable fixed-cost absorption, increased depreciation, and aluminum tariffs in the beer segment. The fixed-cost problem is structural and self-inflicted in the worst way: Constellation built a massive new brewery in Veracruz, Mexico, sized for the volume growth that was supposed to keep coming — and now the volume isn't coming, so the plant runs below capacity and its fixed costs land on a shrinking unit base. That is the denominator illusion running in reverse. You build capacity for a growth curve, the growth curve flattens, and the depreciation and overhead you committed to now crush per-unit margins because there are fewer units to spread them across.

Management made the math explicit by cutting beer operating-margin guidance to 37%–38% from a prior 39%–40%, citing the Veracruz fixed-cost absorption, SG&A increases, and incremental marketing spend. Read that marketing line closely. A brand with genuine structural demand does not need to ramp marketing to defend volumes; the consumer comes to it. When a company simultaneously reports declining flagship depletions and tells you it is spending more on marketing to support the business, those two facts belong in the same sentence. The growth is now being bought with advertising dollars and capacity it overcommitted to, and the margin guidance cut is the receipt. Aluminum tariffs add insult: a Mexican-import brewer is, almost by definition, a commodity price-taker on packaging and a policy-taker on cross-border costs — exposures the bull case rarely prices.

The policy exposure nobody wants to underwrite

There is a risk embedded in Constellation that does not appear on any line of the income statement, and it is precisely the kind of off-statement exposure forensic analysis exists to surface: the company's demand and its supply chain are both unusually sensitive to U.S. policy toward Mexico and toward the Hispanic consumer. Every drop of Constellation's beer is brewed in Mexico and imported, which makes the entire portfolio a standing bet against tariff escalation — and the aluminum-tariff hit already flowing through the margin line is the small, early version of that risk made concrete.

The demand side is more delicate and management knows it, which is why its commentary keeps circling the "evolving socioeconomic backdrop" and "limited near-term visibility" without naming the elephant. Constellation's core consumer skews heavily Hispanic, and a meaningful share of that consumer base is sensitive to immigration enforcement, employment conditions in construction and services, and the general climate of confidence in immigrant communities. When that consumer pulls back — out of economic caution or out of a desire to keep a low profile — it shows up first in exactly the discretionary, on-premise, social-occasion beer purchases that drive Modelo and Corona volumes. The fiscal 2026 depletion decline in the two flagship brands is consistent with precisely that kind of demand softening. The bull case treats Hispanic demographic growth as a permanent tailwind. The fiscal 2026 numbers raise the uncomfortable possibility that the same demographic concentration that was a tailwind on the way up becomes a policy-exposed liability on the way down. You cannot own the demographic upside without owning the demographic downside, and right now the downside is the one showing up in the data.

Adjusted earnings flatter; the GAAP line tells a harsher story

Constellation's headline fourth-quarter print was an adjusted (comparable) EPS of $1.90, which beat the consensus estimate near $1.68 to $1.73 — the kind of beat that generates a reassuring headline. But the GAAP fourth-quarter figure was materially lower, around $1.16 per share, and the gap between those two numbers is where a quality-of-earnings reader earns their keep. Constellation has a long and well-documented history of large non-comparable charges below the adjusted line — most infamously the multi-billion-dollar impairments and losses tied to its Canopy Growth cannabis investment, which culminated in a $1.06 billion impairment recorded back in fiscal 2023 and a string of subsequent markdowns before the company effectively wrote the bet down and walked away.

The Canopy saga is, by now, largely historical — the position has been impaired and exited — but it should permanently color how investors read the difference between Constellation's adjusted and GAAP numbers. This is a management team that asked the market, for years, to look past "non-recurring" cannabis losses that recurred until there was nothing left to lose. When such a team directs you to the adjusted figure and away from a GAAP number nearly forty percent lower, the burden of proof sits with the adjustment, not the skepticism. The full-year reported profit of $1.69 billion and $9.61 of EPS is the number that actually accrued to owners. Investors who anchor only on the comparable $1.90 quarterly beat are reading the version of the income statement that management would prefer they read.

Leverage in a flat-growth world is a different animal

Constellation carries real debt, and for most of the past decade that leverage was benign because it was leverage against a growing cash engine. The company ended fiscal 2026 with comparable net leverage around 2.7x, against a stated target near 3.0x, and it kept its investment-grade rating intact. On its own, that is a manageable balance sheet. The problem is not the absolute number; it is what the number is levered to.

Leverage is a multiplier on the underlying business, and the underlying business just told you its growth engine is guiding to flat. When beer was compounding, 2.7x net leverage was a tailwind — debt-funded buybacks and a growing EBITDA base meant the ratio took care of itself and equity holders enjoyed the amplification. In a world where beer revenue is guided to negative-1%-to-positive-1% and margins are compressing, that same leverage works the other way: a flat-to-down EBITDA base means the leverage ratio drifts the wrong direction unless the company keeps paying it down, which competes directly with the buybacks and the dividend the bull case relies on. Constellation returned more than $1.6 billion to shareholders in fiscal 2026, including roughly $924 million of repurchases, and raised the dividend 1% to $1.03 per quarter. Those returns are funded by a cash engine that is no longer growing. The math of debt plus buybacks plus a dividend is forgiving when revenue rises and unforgiving when it doesn't — and Constellation has just guided to the second world while still spending like it lives in the first.

A de-rated multiple is not the same as a cheap one

The natural rebuttal is that all of this is known — the stock has already de-rated, the multiple has come in, the bad news is priced. And it is true that Constellation no longer trades at the structural-growth premium it once commanded; the market has marked it down toward a defensive-staple multiple. But a cyclical, policy-exposed, single-engine business with declining flagship volumes that has merely de-rated to a staples multiple is not obviously cheap — it may simply be mispriced into the wrong category. The question is not "has it fallen?" but "is the multiple it has fallen to appropriate for the business that is actually showing up in the numbers?"

A genuine consumer-staple — a Coca-Cola, a Procter & Gamble — earns its multiple through broad diversification, low cyclicality, and durable organic volume growth across dozens of products and geographies. Constellation, post-divestiture, is a concentrated bet on Mexican import beer, with two declining flagships, a brand mix rotating toward smaller labels, a policy-exposed consumer, tariff-exposed inputs, an overbuilt brewery dragging fixed-cost absorption, and leverage against a flat cash engine. If beer reaccelerates, today's de-rated multiple is a bargain and the bears look foolish. If beer continues to do what fiscal 2026 showed it doing — drift sideways while the flagships erode — then "de-rated" was the first leg down, not the bottom. A multiple that has fallen is only cheap relative to the earnings it is attached to, and those earnings just told you their growth assumption is no longer safe.

What the bulls genuinely get right

Intellectual honesty demands a real concession here, because the bull case on Constellation is not a fantasy — it is a credible, well-grounded thesis, and several of its load-bearing facts are simply true. Modelo Especial is the number-one beer in the United States by dollar sales, and the beer segment was, per the company's Circana data, the number-one dollar-share gainer in U.S. tracked channels in fiscal 2026. Even in a down year, this portfolio is taking share in an aggregate category that is shrinking — which is a genuinely impressive structural position that most beverage companies would trade almost anything to occupy. A 1% Q4 beer top line and a 2.1% depletion decline, in a U.S. alcohol market that is contracting faster than that, is relative outperformance, not absolute collapse.

The Hispanic demographic tailwind is also real and long-dated: the U.S. Hispanic population continues to grow as a share of the total, and over a multi-decade horizon that is a structural support for Constellation's core consumer that no competitor can replicate. The wine-and-spirits divestiture, whatever else it signals, does genuinely concentrate the company on its highest-margin, highest-return segment and removes a chronic drag on consolidated growth and returns — a cleaner, more focused Constellation is a legitimately better business than the sprawling one that bought Canopy. The balance sheet is investment-grade and the leverage target is being met. And management is returning serious capital — $1.6 billion in fiscal 2026 — to a shareholder base that is being paid to wait. The bull is right that this is a high-quality franchise with a durable demographic edge and a defensible market position. The bear's disagreement is narrower: that the price still embeds growth the most recent numbers no longer demonstrate, and that the concentration which was a strength on the way up is a fragility on the way down.

The kicker

Constellation Brands did not report a catastrophe in fiscal 2026. It reported something more dangerous for a stock priced on a growth premise: a stall. Beer net sales up 1% in the quarter and down 3% for the year. Shipments down 3.8%, depletions down 2.1%, the two flagship brands — Modelo Especial and Corona Extra — in outright volume decline, the slack taken up by labels a fifth their size. Margins compressing 340 basis points on a brewery built for growth that didn't arrive. Wine and spirits liquidated. Guidance for the beer engine set to a flat band straddling zero, with management itself confessing "limited near-term visibility." The bulls are correct that this is the best franchise in a bad category and that the demographics are real. But a company that has sold off its diversification to make a concentrated bet on a single engine, and then watched that engine flatten and its two best cylinders lose compression, is not the structural compounder its history advertised. It is a cyclical, policy-exposed, leveraged single-engine business that has been telling investors a growth story its own depletion data no longer corroborates.

The next time someone calls Constellation the one beer company that grows while America drinks less, point them to the fiscal 2026 depletion table, where Modelo Especial fell about three percent and Corona Extra fell about seven, and ask them which engine, exactly, is still climbing.